Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autonomic Control of the Circulation and VDR (VDR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03513770
Recruitment Status : Recruiting
First Posted : May 2, 2018
Last Update Posted : January 11, 2022
Sponsor:
Information provided by (Responsible Party):
Jian Cui, Milton S. Hershey Medical Center

Tracking Information
First Submitted Date  ICMJE February 15, 2018
First Posted Date  ICMJE May 2, 2018
Last Update Posted Date January 11, 2022
Actual Study Start Date  ICMJE August 14, 2019
Estimated Primary Completion Date July 1, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 9, 2019)
  • Microneurography (MSNA) [ Time Frame: Recorded continuously during the 3-4 hour study visit ]
    This technique provides direct recordings of sympathetic nerve activity directed to blood vessels in skeletal muscle and will be our primary index of sympathoexcitation. This procedure may be performed in the either leg. External mapping of the peroneal or tibial nerve course (10-60 volts, 1-5msec, 1Hz) will be performed just behind the fibular head of the leg or in the popliteal fossa. A reference electrode will be placed subcutaneously about 2-3 cm away from the recording site. Multiunit recordings of MSNA in the leg will be obtained by transcutaneous placement of a tungsten microelectrode (insulated 200 ?m diameter with a tapered un-insulated 1-5 ?m tip) into C-fiber containing fascicle in the nerve. The electrode will be manipulated to yield a neurogram with characteristic bursts of MSNA, that will be amplified, filtered, rectified and integrated to obtain a mean voltage neurogram. Analysis consists of counting burst frequency and amplitude.
  • Vein size with MRI [ Time Frame: Recorded continuously during the 3-4 hour study visit ]
    Forearm cross sectional images will be obtained in HMC MRI facility. The proton weighted images will be obtained with Siemens Magnetom Trio 3T scanner (Siemens Medical Solutions, Erlangen, Germany). Contrast agents are not required for this completely noninvasive technique. The subject will lie supine inside the MRI scanner, and will be instrumented with an cuffs for the wrist-to-elbow occlusion procedure on one arm, and cuffs for automated BP and HR measurements from the other arm, The images will be obtained before and during the wrist-to-elbow occlusion procedure. The sizes of veins (i.e. cross sectional area) will be measured offline.
Original Primary Outcome Measures  ICMJE
 (submitted: April 19, 2018)
Muscle Sympathetic Nerve Activity (MSNA) [ Time Frame: Recorded continuously during the 3-4 hour study visit. ]
MSNA provides direct recordings of sympathetic nerve activity directed to blood vessels in skeletal muscle.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 9, 2019)
  • Heart Rate [ Time Frame: Recorded continuously during the 3-4 hour study visit ]
    Heart rate will be continuously monitored using EKG patch electrodes and monitor (Cardiocap, Datex-Ohmeda, GE Healthcare).
  • Blood Pressure [ Time Frame: Recorded continuously during the 3-4 hour study visit ]
    Systolic and diastolic blood pressure will be monitored using an automatic, non-invasive arm cuff (SureSigns VS3, Philips, Philips Medical Systems), and on the finger with a Finometer (Finapres Medical Systems). Baseline Finometer BP will be adjusted to match the arm cuff BP.
  • Laser-Doppler flowmetry [ Time Frame: Recorded continuously during the 3-4 hour study visit ]
    Skin blood flow will be monitored non-invasively by laser-Doppler flowmetry using special probes taped to the skin. The skin blood flow may be measured from both arms, and legs (up to 4 probes total).
  • Strain gauge [ Time Frame: Recorded continuously during the 3-4 hour study visit ]
    The circumference changes of the forearm will be measured with strain gauges (up to 4 gauges on one arm).
  • Impedance [ Time Frame: Recorded continuously during the 3-4 hour study visit ]
    The electrical impedance or resistance (Zo, in ohms) of a limb segment will be measured, which reflects the total fluid content of the limb. Fluid is an excellent conductor of electricity and the electrical current travels more easily through a ?wet? limb with more blood/fluid volume in the limb. The relative change in Zo will be used as an index for the fluid/blood volume change in a limb segment. By placing 2 pieces of tape with metal strips on the limb, we are able to measure impedance of the limb segment between the tapes.
Original Secondary Outcome Measures  ICMJE
 (submitted: April 19, 2018)
  • Blood pressure in mmHg [ Time Frame: Recorded continuously during the 3-4 hour study visit ]
    Cuffs placed on a finger and arm will monitor blood pressure.
  • Heart rate in beats per minute [ Time Frame: Recorded continuously during the 3-4 hour study visit ]
    Electrocardiogram (ECG) patches attached to a Cardiocap will monitor heart rate.
  • Vein size with MRI [ Time Frame: Recorded continuously during the 3-4 hour study visit ]
    Investigators will measure the magnitude of the venous distention during Ketorolac and saline control trials using MRI
Current Other Pre-specified Outcome Measures
 (submitted: July 9, 2019)
  • Forearm volume [ Time Frame: Baseline ]
    Forearm volume will be measured by the water displacement method. The arm will be placed in the water bath up to the elbow. The baseline limb circumference will also be measured with a tape measure.
  • Biochemistry [ Time Frame: 3 blood draws during the 3-4 hour study visit. ]
    Venous blood samples will be drawn for Thromboxane B2 (TXB2) which will be used as an index for COX blockade, and will be measured in the Pathology laboratory in Hershey Medical Center.
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Autonomic Control of the Circulation and VDR
Official Title  ICMJE Autonomic Control of the Circulation and the Venous Distension Reflex
Brief Summary The study objective of this project is to examine the mechanisms of the venous distension reflex (VDR) in humans. We hypothesize that COX blockade with ketorolac tromethamine, an intravenous NSAID, will attenuate the muscle sympathetic nerve activity (MSNA) response to limb venous distension. To gain further insight into whether the COX byproducts directly stimulate chemically-sensitive afferents, or enable venodilation and indirectly evoke afferent stimulation, we will measure vein size using 3T MRI during venous distention with and without ketorolac infusions.
Detailed Description

We will use a prospective observational design to examine if a COX blockade will inhibit the MSNA response to venous distension (Aim1), and if a COX blockade will alter vein sizes during venous distension (Aim2). Each subject will serve as their own control.

Aim 1:

An IV will be inserted in the antecubital fossa of one arm, and the wrist-to-elbow occlusion will be performed.

To block the COX system, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute (Infusion 1). After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( ~40-60 ml) will be infused into the occluded forearm at a rate of ~ 30 ml/min (Infusion 2). Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.

In the saline control trial, saline (without ketorolac) in identical volumes as those in the COX blockade trial will be performed on a separate day.

Aim 2:

The subject will lie supine inside the MRI scanner. The subject will be instrumented with cuffs for the wrist-to-elbow occlusion procedure on one arm, and cuffs for automated BP and HR measurements from the other arm, The images will be obtained before and during the wrist-to-elbow occlusion procedure. The sizes of veins (i.e. cross sectional area) will be measured offline.

Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
The investigators will examine (using a prospective observational design) if a COX blockade will inhibit the Muscle Sympathetic Nerve Activity response to venous distension, and if a COX blockade will alter vein sizes during venous distension using MRI. Each subject will serve as their own control.
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
These two trials (A and B) will be performed in random order and in a doubleblind fashion for subjects and the data analyzing team. The medical staff who prepare and administrate the drugs and monitor the subject's safety, will not be blinded.
Primary Purpose: Basic Science
Condition  ICMJE
  • Venous Distension Reflex
  • Blood Pressure
Intervention  ICMJE
  • Other: Wrist-to-elbow (W-E) occlusion

    An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.

    First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated.

  • Drug: ketorolac tromethamine
    In the COX blockade trial, just after the Wrist-to-elbow occlusion, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute. After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( ~40-60 ml) will be infused into the occluded forearm at a rate of ~ 30 ml/min. Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.
  • Drug: saline control
    In the saline control trial performed on a separate day, saline (without ketorolac) in identical volumes as those in the COX blockade trial, will be infused.
Study Arms  ICMJE
  • Experimental: Ketorolac
    The Wrist-to-Elbow occlusion procedure will be performed followed by 2 ketorolac tromethamine + saline infusions into the occluded arm.
    Interventions:
    • Other: Wrist-to-elbow (W-E) occlusion
    • Drug: ketorolac tromethamine
  • Placebo Comparator: Control
    The Wrist-to-Elbow occlusion procedure will be performed followed by 2 saline only infusions into the occluded arm.
    Interventions:
    • Other: Wrist-to-elbow (W-E) occlusion
    • Drug: saline control
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 19, 2018)
18
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 1, 2025
Estimated Primary Completion Date July 1, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  • Are capable of giving informed consent
  • Are any race or ethnicity
  • Are fluent in written and spoken English
  • Have a satisfactory history and physical exam to meet inclusion/exclusion criteria
  • Are free of acute or chronic medical conditions
  • Are 21 - 35 years of age (inclusive)
  • Weigh over 50 kg

Exclusion Criteria

  • Are less than 21 or over 35 years of age
  • Are Pregnant or nursing women
  • Are prisoners or institutionalized individuals or unable to consent
  • Any chronic diseases (hypertension, heart, lung, neuromuscular disease, kidney disease, diabetes or cancer).
  • Are taking medications that may affect their cardiovascular or nervous system
  • Has taken an NSAID within 48 hours of any visit (visit will need to be rescheduled)
  • Has never taken NSAIDs and therefore would not know if they are allergic to it
  • Have a supine BP >140/90 mmHg
  • Have known allergy to ibuprofen-like drugs (NSAIDS) or aspirin
  • Have history of asthma or nasal polyps
  • Have history of GI bleeding or ulcers
  • Subjects with ferromagnetic metal implants
  • Subjects who are claustrophobic
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years to 35 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03513770
Other Study ID Numbers  ICMJE STUDY00006585
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Jian Cui, Milton S. Hershey Medical Center
Study Sponsor  ICMJE Milton S. Hershey Medical Center
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Milton S. Hershey Medical Center
Verification Date January 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP